Congress Asset Management’s AtriCure ATRC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-110,094
Closed -$5.43M 375
2023
Q2
$5.43M Buy
110,094
+10,649
+11% +$491K 0.05% 213
2023
Q1
$4.12M Buy
99,445
+9,924
+11% +$412K 0.04% 234
2022
Q4
$3.97M Buy
89,521
+719
+0.8% +$30K 0.04% 231
2022
Q3
$3.47M Buy
88,802
+31,465
+55% +$1.44M 0.04% 228
2022
Q2
$2.34M Buy
57,337
+924
+2% +$43.8K 0.02% 266
2022
Q1
$3.71M Buy
+56,413
New +$3.66M 0.03% 251

Other funds holding ATRC

Congress Asset Management's ATRC Position: Q3 2023 in Review

Congress Asset Management sold out of AtriCure (ATRC) in Q3 2023, closing a stake of 110,094 shares — an estimated $5.43M sold.

Congress Asset Management first reported a position in ATRC in Q1 2022 and held it in 6 quarters. The position peaked at $5.43M in Q2 2023. 230 funds tracked by Wall St. Rank hold ATRC as of Q3 2023.

  • Congress Asset Management reported no remaining AtriCure position as of Q3 2023 after selling out during the quarter.
  • Congress Asset Management sold 110,094 AtriCure shares in Q3 2023, an estimated $5.43M.
  • Congress Asset Management first reported a position in AtriCure in Q1 2022 and held it in 6 quarters.
  • Congress Asset Management's AtriCure position peaked at $5.43M in Q2 2023.
  • 230 funds tracked by Wall St. Rank held AtriCure as of Q3 2023.

Based on Congress Asset Management's 13F filing for Q3 2023, filed 1 Nov 2023.